A retrospective study that pooled five cohorts of HER2+ BC patients found a PIK3CA mutation rate of 21.7% (21.4% in the GeparStudies, 22.5% in NeoALTTO, and 20.4% in the CHERLOB study). This evidence concerns the gene ERBB2 and breast cancer.